Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Subjects Aged 18 to 60 Years in the Republic of Korea
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2016
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Sanofi
- 01 Sep 2016 Status changed from active, no longer recruiting to completed.
- 02 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Sep 2015 New trial record